Antipyretics: Mechanisms of action and clinical use in fever suppression

American Journal of Medicine

Volumn 111, Issue 4, 2001, Pages 304-315

  Aronoff, David M ^a,b   Neilson, Eric G ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Division of Clinical Pharmacology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERMEDIN; ANALGESIC AGENT; ANTIINFLAMMATORY AGENT; ANTIPYRETIC AGENT; ARGIPRESSIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYTOKINE; DRUG METABOLITE; GLUCOCORTICOID; IBUPROFEN; INTERCELLULAR ADHESION MOLECULE 1; N ACETYLIMIDOQUINONE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE INHIBITOR; ROFECOXIB; SALICYLATE SODIUM; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ANTIINFLAMMATORY ACTIVITY; BODY TEMPERATURE; BRAIN LEVEL; BRAIN REGION; CYTOKINE PRODUCTION; DISEASE PREDISPOSITION; DRUG INDICATION; DRUG MECHANISM; ENZYME INHIBITION; FEVER; HUMAN; HYPOTHALAMUS; INFECTION; LEUKOCYTE ADHERENCE INHIBITION; LEUKOCYTE MIGRATION; LIVER TOXICITY; NERVE CONDUCTION; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; THERMOREGULATION;

BODY TEMPERATURE REGULATION; CELL ADHESION MOLECULES; CYTOKINES; FEVER; HUMANS; INFLAMMATION MEDIATORS; PROSTAGLANDINS E;

EID: 0034827525     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(01)00834-8     Document Type: Review

References (96)

1. Wagner-Jauregg and fever therapy
2. Benefits and risks of antipyretic therapy
3. Cinchona and its alkaloids: 350 Years
4. The miraculous willow tree
5. Brief history of antipyretic therapy
6. Sur des nouveaux produits extraits de la salicin
7. The history and usage of paracetamol
8. Aspirin
9. Normal "body" temperature
10. Thermoregulation
11. The neurologic basis of fever
12. Cytokines and fever: Mechanisms and sites of action
13. Fever: Links with an ancient receptor
14. Impaired febrile response in mice lacking the prostaglandin E receptor subtype EP3
15. Relationship of EP(1-4) prostaglandin receptors with rat hypothalamic cell groups involved in lipopolysaccharide fever responses
16. Fever and antipyresis
17. Attenuation of proinflammatory response by recombinant human IL-10 in human endotoxemia: Effect of timing of recombinant human IL-10 administration
18. An antipyretic role for interleukin-10 in LPS fever in mice
19. Role of cytochrome P-450 in endogenous antipyresis
20. Molecular mechanisms of fever and endogenous antipyresis
21. Exposure to febrile temperature upregulates expression of pyrogenic cytokines in endotoxin-challenged mice
22. Febrile core temperature is essential for optimal host defense in bacterial peritonitis
23. Role and regulation of cyclooxygenase-2 during inflammation
24. The febrile response to lipopolysaccharide is blocked in cyclooxygenase- 2(-/-), but not in cyclooxygenase-1(-/-) mice
25. Cyclooxygenase-2 inhibition by rofecoxib reverses naturally occurring fever in humans
26. Endothelial cells of the rat brain vasculature express cyclooxygenase-2 mRNA in response to systemic interleukin-1 beta: A possible site of prostaglandin synthesis responsible for fever
27. Brain endothelial cells express cyclooxygenase-2 during lipopolysaccharide-induced fever: Light and electron microscopic immunocytochemical studies
28. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs
29. Aspirin
30. Inhibition of prostaglandin synthetase in brain explains the anti-pyretic activity of paracetamol (4-acetamidophenol)
31. NSAIDs: Aspirin and aspirin-like drugs
32. Comparison of the cyclooxygenase-1 inhibitory properties of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors, using sensitive microsomal and platelet assays
33. Suppression of inducible cyclooxygenase 2 gene transcription by aspirin and sodium salicylate
34. Nuclear factor-kappaB: A pivotal transcription factor in chronic inflammatory diseases
35. Transcriptional regulation of cyclooxygenase-2 in the human microvascular endothelial cell line, HMEC-1: Control by the combinatorial actions of AP2, NF-IL-6 and CRE elements
36. Function and activation of NF-kappa B in the immune system
37. Aspirin inhibits tumor necrosis factor-alpha gene expression in murine tissue macrophages
38. Salicylates inhibit I kappa B-alpha phosphorylation, endothelial-leukocyte adhesion molecule expression, and neutrophil transmigration
39. Acetylsalicylic acid and sodium salicylate inhibit LPS-induced NF-kappa B/c-Rel nuclear translocation, and synthesis of tissue factor (TF) and tumor necrosis factor alfa (TNF-alpha) in human monocytes
40. Inhibition of NF-kappa B by sodium salicylate and aspirin
41. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta
42. Constitutive activation of IkappaB kinase alpha and NF-kappaB in prostate cancer cells is inhibited by ibuprofen
43. Acetaminophen inhibits iNOS gene expression in RAW 264.7 macrophages: Differential regulation of NF-kappaB by acetaminophen and salicylates
44. Sites of action for future therapy: An adenosine-dependent mechanism by which aspirin retains its antiinflammatory activity in cyclooxygenase-2 and NFkappaB knockout mice
45. Modes of action of aspirin-like drugs: Salicylates inhibit erk activation and integrin-dependent neutrophil adhesion
46. Lipoxins and novel aspirin-triggered 15-epi-lipoxins (ATL): A jungle of cell-cell interactions or a therapeutic opportunity?
47. Central vasopressin V1-blockade prevents salicylate but not acetaminophen antipyresis
48. Ibuprofen inhibits pyrogen-dependent expression of VCAM-1 and ICAM-1 on human endothelial cells
49. Salicylates and sulfasalazine, but not glucocorticoids, inhibit leukocyte accumulation by an adenosine-dependent mechanism that is independent of inhibition of prostaglandin synthesis and p105 of NFkappaB
50. Effect of high-dose ibuprofen in patients with cystic fibrosis
51. Ibuprofen inhibits leukocyte migration through endothelial cell monolayers
52. Nonsteroidal antiinflammatory agents inhibit stimulated neutrophil adhesion to endothelium: Adenosine dependent and independent mechanisms
53. Non-steroidal anti-inflammatory drugs inhibit the expression of cytokines and induce HSP70 in human monocytes
54. Prevention of in vitro neutrophil-endothelial attachment through shedding of L-selectin by nonsteroidal antiinflammatory drugs
55. Regulation of adhesion molecules during human endotoxemia: No acute effects of aspirin
56. Studies on the antipyretic action of salicylates
57. Acetaminophen has greater antipyretic efficacy than aspirin in endotoxemia: A randomized, double-blind, placebo-controlled trial
58. Detection of circulating tumor necrosis factor after endotoxin administration
59. Detection of interleukin 8 and tumor necrosis factor in normal humans after intravenous endotoxin: The effect of antiinflammatory agents
60. Pretreatment with ibuprofen augments circulating tumor necrosis factor-alpha, interleukin-6, and elastase during acute endotoxinemia
61. Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5"-nucleotidase-mediated conversion of adenine nucleotides
62. Adenosine. An endogenous inhibitor of arachidonic acid release and leukotriene biosynthesis in human neutrophils
63. Local and systemic delivery of a stable aspirin-triggered lipoxin prevents neutrophil recruitment in vivo
64. Anti-inflammatory actions of lipoxin A(4) stable analogs are demonstrable in human whole blood: Modulation of leukocyte adhesion molecules and inhibition of neutrophil-endothelial interactions
65. Central vasopressin V1-receptors mediate indomethacin-induced antipyresis in rats
66. Vasopressin release within the ventral septal area of the rat brain during drug-induced antipyresis
67. Drug therapy. Acetaminophen
68. Paracetamol plasma and cerebrospinal fluid pharmacokinetics in children
69. Effect of bacterial pyrogen and antipyretics on prostaglandin activity in cerebrospinal fluid of unanaesthetized cats
70. Release and actions of prostaglandins in inflammation and fever: Inhibition by anti-inflammatory and antipyretic drugs
71. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase
72. Induction of an acetaminophen-sensitive cyclooxygenase with reduced sensitivity to nonsteroid antiinflammatory drugs
73. Mechanism of acetaminophen inhibition of cyclooxygenase isoforms
74. Inflammatory molecule release by beta-amyloid-treated T98G astrocytoma cells: Role of prostaglandins and modulation by paracetamol
75. Role of fever in disease
76. The adaptive value of fever
77. Febrile convulsions
78. Randomized, controlled trial of ibuprofen syrup administered during febrile illnesses to prevent febrile seizure recurrences
79. Antipyretic effectiveness of acetaminophen in febrile seizures: Ongoing prophylaxis versus sporadic usage
80. Coronary vasoconstrictor effect of indomethacin in patients with coronary-artery disease
81. Cardiovascular alterations during fever
82. Treatment of fever in 1982: A review
83. Haemolytic streptococcal gangrene and non-steroidal anti-inflammatory drugs
84. Acetaminophen: More harm than good for chickenpox?
85. Effect of paracetamol on parasite clearance time in Plasmodium falciparum malaria
86. Fulminant necrotizing fasciitis and nonsteroidal anti-inflammatory drugs
87. Increased virus shedding with aspirin treatment of rhinovirus infection
88. Activation of latent infection by indomethacin: A report of three cases
89. The effects of ibuprofen on the physiology and survival of patients with sepsis
90. Effects of ibuprofen on the physiology and survival of hypothermic sepsis
91. Rhinovirus stimulation of interleukin-6 in vivo and in vitro. Evidence for nuclear factor kappa B-dependent transcriptional activation
92. Profile and mechanisms of gastrointestinal and other side effects of nonsteroidal anti-inflammatory drugs (NSAIDs)
93. Over-the-counter analgesics and antipyretics: A critical assessment
94. Antipyretic therapy: Clinical trials 1990 through 1995
95. Vagus nerve in fever. Recent developments